Shareholder Investigation of Surface Oncology
Robbins LLP is Investigating Surface Oncology, Inc. (SURF)
Robbins LLP informs shareholders that it is investigating Surface Oncology (NASDAQ: SURF) for potential violations of federal securities laws pursuant to its April 2018 initial public offering (“IPO”). Surface Oncology completed its IPO on April 23, 2018, offering shares at $15.00. Since its IPO, Surface Oncology’s stock has plummeted, and currently trades at $2.06, or less than 85% of its IPO price. Surface Oncology is a clinical-stage immune-oncology company that engages in the development of cancer therapies.
Surface Oncology, Inc. (SURF) Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can send us a message via the Shareholder Information below.